Tyrosine Kinase Inhibitors: all 10,479 studies that test it
Page 71 of 105. Open to participants first (1,915), then studies with results posted, then the rest; newest registration first within each.
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1
- Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive ChemotherapyStatus unknownNCT03792542Phase 2
- Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based RegimenWithdrawnNCT03792503Phase 4
- Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
- Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03790332Phase 1/2
- Rogaratinib (BAY1163877) in Chinese PatientsCompletedNCT03788603Phase 1
- Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With ApatinibWithdrawnNCT03787251Phase 2
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung CancerStatus unknownNCT03781869Phase 2
- Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered TumorsCompletedNCT03780517Phase 1
- Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLCStatus unknownNCT03780283Phase 2
- Alectinib in Combination With Bevacizumab in ALK Positive NSCLCCompletedNCT03779191Phase 2
- Lenvatinib Plus PD-1 Antibody for Unresectable ICCSuspendedNCT03779100Phase 2
- Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)Status unknownNCT03778853Phase 4
- Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCStatus unknownNCT03778138Phase 2
- Effects of Tucatinib on Cardiac Repolarization in Healthy ParticipantsCompletedNCT03777761Phase 1
- Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03777124Phase 2
- Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast CancerStatus unknownNCT03775928Phase 2
- Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2
- HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3
- Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnNCT03772288Phase 1
- Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsCompletedNCT03771040Phase 3
- A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Status unknownNCT03770988Phase 2
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
- Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLCStatus unknownNCT03769805Not applicable
- Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLCStatus unknownNCT03768037Phase 4
- Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03766776Not applicable
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNCT03766490Not applicable
- Masitinib Plus Gemcitabine in Pancreatic CancerCompletedNCT03766295Phase 3
- Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeStatus unknownNCT03765775Phase 2
- Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different FormulationsCompletedNCT03765554Phase 1
- Nilotinib in Huntington's DiseaseStatus unknownNCT03764215Phase 1
- ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZCompletedNCT03762928Phase 1
- Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedNCT03762122Phase 2
- Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerCompletedNCT03761225Phase 3
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasTerminatedNCT03761069Phase 1
- Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M MutationStatus unknownNCT03758677Phase 2
- Clinical Study of ICP-192 in Solid Tumors PatientsStatus unknownNCT03758664Phase 1/2
- A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy ParticipantsCompletedNCT03758339Phase 1
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedNCT03758287Phase 1/2
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
- Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerStatus unknownNCT03756064Not applicable
- Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
- Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）Status unknownNCT03755869Phase 4
- A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedNCT03755102Early Phase 1
- X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2
- A Taste Assessment of BMS-986165 in Healthy ParticipantsCompletedNCT03751228Phase 1
- Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung CancerStatus unknownNCT03750916Phase 2
- Multiple Dose Ethnobridging PK Study in Healthy SubjectsCompletedNCT03750565Phase 1
- Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
- Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
- Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)SuspendedNCT03743428Not applicable
- Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）CompletedNCT03743129Phase 2
- Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedNCT03742349Phase 1
- Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy ParticipantsCompletedNCT03742336Phase 1
- TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCTStatus unknownNCT03741244Phase 2
- An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCompletedNCT03739788Phase 1
- Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical TrialStatus unknownNCT03738956Phase 2/3
- Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedNCT03736837Phase 2
- Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisCompletedNCT03736161Phase 3
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
- Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）Status unknownNCT03735264Phase 2
- Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
- Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 DysfunctionActive, not recruitingNCT03734198Phase 2
- Anlotinib in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03732846Phase 2
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
- Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid CarcinomasStatus unknownNCT03732495Phase 2
- 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompletedNCT03732352Phase 2
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingNCT03731260Phase 2
- Ibrutinib + R-CHOP Followed by Ibrutinib MaintenanceActive, not recruitingNCT03731234Phase 2
- Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1
- Cabozantinib in Advanced Salivary Gland Cancer PatientsTerminatedNCT03729297Phase 2
- Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaStatus unknownNCT03728374Phase 2
- A Study of AZD4205 in Healthy Adult SubjectsCompletedNCT03728023Phase 1
- Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
- Apatinib for Advanced Lung Squmamous CarcinomaStatus unknownNCT03725423Phase 4
- Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-EvobrutinibCompletedNCT03725072Phase 1
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisActive, not recruitingNCT03725007Phase 1
- Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedNCT03723395Phase 1
- SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Not applicable
- A Safety Study of Tucatinib in Healthy and Hepatically-Impaired SubjectsCompletedNCT03722823Phase 1
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingNCT03722420Phase 3
- Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
- EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT03720873Phase 2
- Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
- A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT03718624Phase 2
- Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1
- Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLCTerminatedNCT03711422Phase 1
- Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2
- Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid CarcinomaStatus unknownNCT03709953Phase 2
- Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
- Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03707938Phase 1
- Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCLStatus unknownNCT03707847Phase 4
- Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2